The second patient was a 55-year-old woman who developed neurologic and eye symptoms due to sarcoidosis. Corticosteroid therapy was begun with an initial dosage of 30 mg of prednisolone per day, and serum concentration of soluble IL-2R decreased rapidly to the normal range within four weeks, accompanied by improvement of her symptoms and a decrease in serum ACE activity (Fig 3B). A similar rapid decrease in both the serum soluble IL-2R level and ACE activity also was noted in other patients who received corticosteroid treatment (data not shown).
The third case was a 33-year-old man who manifested the disease with uveitis and BHL. Corticosteroid therapy had been started at another hospital (initial dosage of 30 mg of prednisolone daily), which was continued for eight months; resolution of eye symptoms and chest abnormalities evidenced radiologically ensued. After cessation of the therapy, reappearance of chest abnormalities evidenced radiologically and elevation of serum concentration of soluble IL-2R and ACE activity were noted (Fig 3C). buy asthma inhaler
In the present study, we confirmed that serum concentrations of soluble IL-2R were elevated in untreated patients with active sarcoidosis as compared with healthy controls. The level in untreated active sarcoidosis was significantly higher than in those with dormant or treated sarcoidosis. In patients with spontaneous remission, the level gradually fell to normal range along with the resolution of chest abnormalities evidenced radiologically.